Approval · Notice of Compliance 35725 · 2025
BLENREP: Notice of Compliance 35725
Issued July 21, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35725
- Date
- July 21, 2025
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BLENREP | Not yet assigned | — |
Medicinal ingredients
- BELANTAMAB MAFODOTIN 100 MG per VIAL
- BELANTAMAB MAFODOTIN 70 MG per VIAL